Disc’s once-spurned rare disease drug to get a second chance at approval
Source ↗
👁 0
💬 0
Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.
Comments (0)